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A B S T R A C T
Introduction: Transforming growth factor-beta 1(TGF-b1) is a regulatory protein, involved in bone
fracture healing. Circulating TGF-b1 levels have been reported to be a predictor of delayed bone healing
and non-union, suggesting active relationship between tissue and circulating TGF-b1 in fracture healing.
The purpose of this study was to analyse TGF-b1 local and serum concentrations in fracture healing to
further contribute to the understanding of molecular regulation of fracture healing.
Patients and methods: Serum samples of 113 patients with long bone fractures were collected over a
period of 6 months following a standardised time schedule. TGF-b1 serum concentrations were
measured using ELISA. Patients were assigned to 2 groups: Group 1 contained 103 patients with
physiological healing. Group 2 contained 10 patients with impaired healing. Patients in both groups were
matched. One patient of the group 2 had to be excluded because of missing match partner. In addition,
fracture haematoma from 11 patients of group 1 was obtained to analyse local TGF-b1 concentrations.
33 volunteers donated serum which served as control.
Results: TGF-b1 serum concentrations increased during the early healing period and were signiﬁcantly
higher in patients with physiological healing compared to controls (P = 0.04). Thereafter, it decreased
continuously between weeks 2 and 8 and fell again after week 8. TGF-b1 serum concentrations in
patients with physiological healing were signiﬁcantly higher at week 24 compared to controls (P = 0.05).
In non-unions, serum concentrations differed signiﬁcantly from those of controls at week 6 (P = 0.01). No
signiﬁcant difference in between patients with physiological and impaired fracture healing was
observed. Fracture haematoma contained signiﬁcantly higher TGF-b1 concentrations than peripheral
serum of the patients (P = 0.017).
Conclusion: Elevated levels of TGF-b1 in haematoma and in serum after bone fracture especially during
the entire healing process indicate its importance for fracture healing.
 2011 Elsevier Ltd. 
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Open access under CC BY-NC-ND license.gated during the last ten years. Many studies have focused on the
roles of cytokines and growth factors in fracture healing.1–4 More
than ﬁfty cytokines, angiogenic factors, proteases and morphogens
with signiﬁcant roles in fracture healing, have been described.2
However, despite intensive research most of the regulation
mechanisms are not well understood.1 Evidence exists that the
local and systemic concentrations of certain cytokines are
increased during fracture healing.2,4–6 TGF-b1, a member of
TGF-b family, is a regulatory protein involved in bone remodelling
and fracture healing.7–9 TGF-b1 plays a pivotal role in the process
of fracture healing10–17 as it enhances the proliferation and
differentiation of mesenchymal stem cells (MSCs), increases the
production of extracellular matrix and is chemotactic on bone
cells.18 It has a key role on the promotion of cartilage formation and
increases the formation of callus and bone strength.10,17 TGF-b1
has been shown to have a stimulating effect on bone healing in
several animal studies.11–16 For example systemic application of
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bone defect11 and local application of TGF-b1 has been shown to
accelerate fracture healing.19 The presence of TGF-b1 in callus has
been reported in human and animal fracture models.5,19–23 In
addition, evidence exists that serum concentrations of TGF-b1 are
increased during the process of bone healing.4 Circulating TGF-b1
levels were found to be a predictor of delayed bone healing and
non-union suggesting active relationship of its circulating levels to
fracture healing process.4 To our knowledge, only few data exist on
systemic and local measurement of TGF-b1 with regard to fracture
healing in humans so far. The aim of our study was to analyse the
local and systemic levels of TGF-b1 expression after bone fracture
in patients with physiological and impaired fracture healing for
better understanding of the role of this cytokine in the process of
human fracture healing.
Patients and methods
This study was approved by the Ethic Committee of the Medical
University of Vienna and performed in accordance with the ethical
standards in the Declaration of Helsinki. A consecutive series of
113 patients with meta-/diaphyseal fractures of long bone
(humerus, femur, lower leg and forearm) treated surgically at
our institution between April 2006 and April 2008, were included.
Patients gave informed consent to be enrolled in the study, and
were 18–90 years old. Exclusion criteria were open fractures type
III according to the Gustilo classiﬁcation, multiple fractures,
previous bone operations, pre-existing bone diseases except for
osteoporosis, renal/liver insufﬁciency, malignant tumours, long
term steroid treatment, immunosuppression and long term
treatment with non-steroidal anti-inﬂammatory drugs. Patients
were assigned in 2 groups according to their course of fracture
healing. The ﬁrst group contained 103 patients (male n = 50,
female n = 53, mean age: 54.2  20.4) with normal fracture healing.
Ten patients with impaired fracture healing (delayed- or non-union)
belonged to the second group. Three of the 10 patients developed a
hypertrophic type of delayed union. Seven patients developed an
atrophic type of delayed union. Demographics presented in Table 1.
The diagnosis of bony consolidation or delayed union was based on
exercise-induced pain and conventional X-rays or computed tomog-
raphy. Delayed union was deﬁned as failed fracture healing without
radiological signs of bony consolidation after 4 months postopera-
tively. Non union was deﬁned as the absence of complete consolida-
tion at 6 months after surgery. A corresponding patient with normal
fracture healing and a healthy control was matched to each patient
with delayed fracture healing. Table 1 presents the demographics of
patients and the matching criteria. One of the 10 patients with
delayed fracture healing had to be excluded, because no correspond-
ing matching partner with adequate fracture healing could be found
in our study cohort. Therefore, 9 patients with impaired and 9Table 1
Matching criteria and demographics of the matched patients from both groups.
No Sex Agea Fracture typeb Location Soft-tissue damagec Fixation 
Physiological healing 
1 M 42 42-A Tibia/ﬁbula 0 Screw/plate 
2 M 23 32-A Femur 0 Nail 
3 M 59 42-A Tibia/ﬁbula 0 Nail 
4 M 32 13-C Humerus 0 Plate 
5 M 50 11-A Humerus 0 Nail 
6 M 66 31-A Femur 0 Nail 
7 M 70 42-A Tibia/ﬁbula 0 External ﬁxator
8 F 57 42-C Tibia II8 External ﬁxator
9 F 38 42-A Tibia I8 Nail 
a Age (10 years).
b According to ASIF classiﬁcation.
c Extent of soft tissue damage according to Gustilo classiﬁcation.patients with normal fracture healing were included in the ﬁnal
analyses.
In addition, fresh fracture haematoma was obtained from 11
patients of group 1 intra-operatively to analyse local TGF-b1
concentrations. Furthermore, 33 healthy volunteers (16 males, 17
females, mean age: 37.1  11.65 years) donated one blood sample as
control.
All patients were followed up for at least six months after the
operation. The follow up examination was based on clinical and
radiological examination at 1, 2, 4, 6, 8, 12, 24 weeks after trauma.
Blood samples
Peripheral venous blood was obtained from each patient at 1, 2,
4, 6, 8, 12, 24 weeks after surgery and stored at 80 8C until
analysis. TGF-b1 serum concentration was measured in 11
patients immediately after trauma at hospital admission. Each
control individual donated one blood sample. Fracture haematoma
was obtained at surgery. Haematoma was removed manually
before any manipulation or irrigation, avoiding contamination by
blood in the operating ﬁeld, and placed in sterile containers. These
specimens were centrifuged immediately and the resulting
supernatant was stored at 80 8C until assayed.
Measurement of TGF-b1
TGF-b1 concentrations were measured by a commercially
available antibody (Quantikine, RD Systems, Minneapolis, MN,
USA) in enzyme-linked immuno sorbent assay (ELISA). All
analytical steps were performed according to the manufacturer’s
recommended protocol. The TGF-b1 assay detects speciﬁcally the
biologic active form of the protein. Concentrations are presented as
mean of duplicate measurements. To avoid interassay variability,
samples of the corresponding matching partner were analysed
with the same assay. The comparison of the measurements
utilising different Kits for the same time points of the study
measurements indicates the low range of variability of the assays.
Statistical analysis
Comparisons between groups of continuous variables were
performed by using non-parametric ANOVA (Wilcoxon rank-sum
test for two variables or Kruskal–Wallis-Test for more than two
variables). For statistical comparison of a serum value at a certain
time point between the non-union group and the matched unions
nonparametric Mann–Whitney U test for unpaired samples were
used. Statistical analyses were performed using the SAS system for
Windows, v 9.1 and the Enterprise Guide, v 4.1 (SAS Institute, Inc.,
Cary, NC). Data are presented as means  SEM. The statistical
signiﬁcance level was set at P < 0.05.Sex Age Fracture type Location Soft-tissue damage Fixation
Impaired healing
F 52 42-A Tibia/ﬁbula 0 Screw/plate
M 24 32-A Femur 0 Nail
M 63 42-A Tibia/ﬁbula 0 Nail
M 42 13-C Humerus 0 Plate
M 55 11-A Humerus 0 Plate
F 82 31-A Femur 0 Nail
 M 63 42-A Tibia/ﬁbula 0 External ﬁxator
 M 53 42-C Tibia II8 External ﬁxator
F 37 42-A Tibia I8 Nail
Fig. 2. Time course of TGF-b1 concentrations (mean  SEM) in matched patients
with physiological (unions) or impaired fracture healing (non-unions) after surgery for
long-bone fractures.
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TGF-b1 serum concentrations in patients with physiological and
impaired fracture healing
TGF-b1 serum concentration immediately after injury (mea-
sured in 11 patients) was 14,171.2  5642.66 pg/ml. TGF-b1 serum
concentrations were at a minimum level at 1 week (29,178.0
 1364.29 pg/ml) and increased to reach a maximum level
(36,334.0  1688.3 pg/ml) at 2 weeks after trauma (P = 0.0001). Serum
concentrations decreased continuously after week 2 and reached
another minimum concentration (31,932.4  1397.0 pg/ml) at week 8
after trauma. After week 8, a continuous increase of the TGF-b1 serum
concentrations was observed. A second peak of the TGF-b1 serum
concentration was observed at week 24 after trauma
(35,267.7  2220.3 pg/ml) (Fig. 1). In patients with impaired fracture
healing TGF-b1 serum concentrations were at a minimum level
(27,339.7  2973.45 pg/ml) at week 1 and increased to reach a ﬁrst
peak at week 2 (34,265.8  4337.3 pg/ml), which was followed by a
clear decline at week 4 after trauma (27,939.6  3327.7 pg/ml).
Between week 4 and 6 a signiﬁcant increase of the TGF-b1 serum
concentrations were observed (P = 0.03). TGF-b1 serum concentrations
were highest at week 6 after fracture (43,294.1  4949.5 pg/ml).
Thereafter, a continuous decline of the serum levels was observed for
the rest of the observation period (Fig. 1).
Comparison of TGF-b1 serum concentrations in patients with normal/
impaired healing
Comparison of TGF-b1 serum concentrations between the
matched patients with normal and impaired healing revealed no
statistically signiﬁcant difference for the entire observation period
(Fig. 2).
Comparison of TGF-b1 serum concentrations between controls and
patients
Comparison of TGF-b1 serum concentrations of patients with
normal fracture healing and controls (29,735.3  1328.4 pg/ml)
revealed signiﬁcant differences at weeks 2 (P = 0.04) and 24 (P = 0.05).Fig. 1. TGF-b1 serum concentrations (mean  SEM) in controls and in patients with
long-bone fractures and physiological (unions) or impaired fracture healing (non-
unions). Asterisks indicate signiﬁcant differences in TGF-b1 concentrations between
unions and controls (P = 0.04 at week 2 and P = 0.05 at week 24). ySigniﬁcant
differences in TGF-b1 concentrations between non-unions and controls (P = 0.01).At these time points signiﬁcantly higher TGF-b1 concentration were
observed in patients with normal healing compared to controls.
Comparison between the TGF-b1 serum concentrations of patients
with impaired fracture healing and controls showed signiﬁcantly
higher TGF-b1 serum concentrations in patients with impaired
healing at week 6 (P = 0.01).
To exclude that the differences in TGF-b1 serum levels between
the patients and the controls are related to the age difference
between the both groups (mean age: 35.6 vs. 54.2) an additional
analysis with an age matched group was performed. This analysis
revealed no age related difference in the TGF-b1 serum level
between both matched groups and conﬁrmed the reported results.
Comparison of TGF-b1 concentration in fracture haematoma and in
serum of patients
Mean TGF-b1 concentration measured in fracture haematoma
was 28,157  6282.6 pg/ml. Mean TGF-b1 serum concentrations was
14,171.2  2132.7 pg/ml. Fracture haematoma contained signiﬁcant-
ly higher TGF-b1 concentration than serum (P = 0.017) (Fig. 3).
Discussion
Various studies demonstrated that fracture repair is not a local
process but is rather associated with systemic reactions that might
partly be attributable to the uptake of bioactive molecules from the
fracture site.12,24,25 In the present study, local and systemicFig. 3. TGF-b1 concentrations (mean  SEM) in fracture haematoma and serum of
patients. Asterisk indicates signiﬁcant difference in TGF-b1 concentrations (P = 0.017).
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were analysed to elucidate the role of this osteogenic cytokine in
the bone healing process. Previous studies showed characteristic
alterations in serum concentrations of numerous enzymes and
growth factors during fracture healing.3–5,26 Consistently, we
found signiﬁcant alterations in local and systemic distribution of
TGF-b1 at certain time points after fracture of long bones. TGF-b1
concentrations in fracture haematoma were signiﬁcantly higher
than serum concentrations within the ﬁrst hours after trauma
indicating local release of TGF-b1 during the immediate response
in concert with previous studies.2,4,8,16,25 Our data show a
considerable ﬂuctuation of the systemic TGF-b1 concentration
within the ﬁrst weeks of fracture healing. Whilst the mean post-
traumatic serum TGF-b1 level in those 11 patients with
immediate post-traumatic measurement was 14,171 pg/ml, the
mean TGF-b1 serum concentration of the rest of the patients as
well as half of the control-baseline of the healthy volunteers was
almost twofold high at one week after trauma. Due to the fact that
TGF-b1 is released from granulas of platelets during the clotting
process, high local TGF-b1 concentrations in fracture haematoma
of our patients do not appear surprisingly.27 An earlier study
showed that TGF-b1 is released by platelets into the fracture
haematoma, and then synthesised by osteoblasts and chondrocyts
throughout the healing process.27 This explains the following
increase of serum TGF-b1 concentrations within the ﬁrst 2 weeks
after trauma in our patients. Increased expression of TGF-b1 as
well as other cytokines early after fracture was reported in other
studies.6,28–32 This increase may partly be attributable to the
absorption of cytokines from the fracture site into the circula-
tion.12,33,34 On the other hand, the signiﬁcant increase of serum
TGF-b1 concentrations together with other cytokines such as
PDGF, VEGF and M-CSF might indicate a systemic response to
fracture. Supporting inﬂuence of systemic parameters on bone
formation is well known and was demonstrated in previous
studies.35,36 Maximum serum TGF-b1 concentrations during the
intramembranous bone formation phase might give evidence for
the chemotactic effect of TGF-b1 on bone cells. It is well known
that an increasing number of osteoblasts, chondroblasts and
immature progenitor cells invade the fracture area during the
phase of intramembranous bone formation.33 Moreover, TGF-b1
is reported to stimulate bone formation by inducing differentia-
tion of subperosteal mesenchymal cells into osteoblasts,9,37
which synthesise and release TGF-b1 by themselves at the
proliferations stage and again exert stimulating effects on
osteoblasts in an autocrine fashion.8,38,39
TGF-b1 concentrations started to decrease and reached a
plateau between weeks 4 and 8. We believe that this continuous
decrease of TGF-b1 serum concentration might be due to the
increasing gain of mechanical stability of the fracture, as suggested
by other clinical studies.3,33,34 For the later course, our data
demonstrate that TGF-b1 serum concentrations in patients with
bone fractures remain elevated during the remodelling phase; and
this seems to be necessary to activate osteoblasts during the
remodelling phase. On the other hand, osteoblasts activate TGF-b1
during the remodelling phase which might explain signiﬁcantly
high TGF-b1 serum concentration at week 24.40 TGF-b1 expres-
sion pattern observed in our patients is in agreement with previous
animal and human studies.4,30 Moreover, the expression pattern of
TGF-b1 was very similar to that of M-CSF and VEGF. In previously
published studies, our group observed an almost identical course
of TGF-b1 levels compared to M-CSF for the entire observation
period and a very similar course compared to VEGF until week 8
after fracture.31,32 These ﬁndings indicate that not only the local
presence of the osteogeneic growth factors but also their systemic
presence is necessary to support fracture healing. Therefore, we
suggest that whenever osteogenic growth factors are clinically orexperimentally utilised for the enhancement of fracture healing,
they should be used locally and systemically.
Another question addressed in our study was whether TGF-b1
expression differs in patients with impaired fracture healing from
those with physiological fracture healing. Since previous studies
showed decreased serum concentrations of TGF-b1 with increas-
ing age and in females6 we generated 2 homogenous groups with 9
patients to reduce the inﬂuence of treatment modalities, gender
and age. Therefore, to each patient with impaired fracture healing a
patient with physiological fracture healing was matched. As
previously mentioned continuous decline of TGF-b1 serum
concentrations during the plateau phase in patients with normal
fracture healing was assumed to be caused by an increase of the
mechanical stability of the fracture. Elevated TGF-b1 serum
concentrations at week 6 in patients with impaired healing
reﬂects the opposite course compared to normally healed patients
and might be due to a lack of mechanical stability at that time. TGF-
b1 serum concentrations of both groups were very similar for the
rest of the observation period in our study. In contrast to results
reported by Zimmermann et al4 we observed no signiﬁcant
differences in the TGF-b1 concentrations of patients with
physiological and disturbed fracture healing. To exclude the only
possible explanation for this discrepancy another analysis, i.e. only
in patients with atrophic type of non union, was performed.
However, the results did not reveal a signiﬁcant difference.
Finally, this study provides prospectively collected data on
systemic levels of TGF-b1 over the entire period of fracture healing
in a large collective of patients and data on local TGF-b1
concentrations in a smaller collective of patients with physiologi-
cal fracture healing which may contribute to the understanding of
molecular regulation of fracture healing. One limitation of this
study is the small number of patients with impaired fracture
healing. However, strictly chosen matching criteria enabled us to
compare the data of patients with impaired fracture healing with
those who had physiological healing.
Elevated levels of TGF-b1 in haematoma and in serum after
bone fracture indicate its involvement in the human fracture
healing. Signiﬁcant differences in TGF-b1 levels of patients with
physiological and impaired fracture healing could not be observed.
Deﬁnitely further studies with higher number of patients with
impaired fracture healing are needed to clarify the role of TGF-b1
in fracture healing.
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